Evidence map›Paper›PMID 34833028›Full record

ReviewLife (Basel, Switzerland)2021

What Happens to the Immune System after Vaccination or Recovery from COVID-19?

Bruna T Tiyo, Gabriela J H Schmitz, Marina M Ortega, Laís T da Silva, Alexandre de Almeida, Telma M Oshiro, Alberto J da S Duarte

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bruna T TiyoLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM 56), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, BR. Av. Dr. Enéas Carvalho de Aguiar, 470. IMT II, 3° Andar, São Paulo 05403-000, SP, Brazil.ORCID 0000-0002-8107-9536
Gabriela J H SchmitzLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM 56), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, BR. Av. Dr. Enéas Carvalho de Aguiar, 470. IMT II, 3° Andar, São Paulo 05403-000, SP, Brazil.ORCID 0000-0002-7069-1017
Marina M OrtegaLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM 56), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, BR. Av. Dr. Enéas Carvalho de Aguiar, 470. IMT II, 3° Andar, São Paulo 05403-000, SP, Brazil.
Laís T da SilvaLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM 56), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, BR. Av. Dr. Enéas Carvalho de Aguiar, 470. IMT II, 3° Andar, São Paulo 05403-000, SP, Brazil.
Alexandre de AlmeidaLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM 56), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, BR. Av. Dr. Enéas Carvalho de Aguiar, 470. IMT II, 3° Andar, São Paulo 05403-000, SP, Brazil.ORCID 0000-0002-1694-5450
Telma M OshiroLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM 56), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, BR. Av. Dr. Enéas Carvalho de Aguiar, 470. IMT II, 3° Andar, São Paulo 05403-000, SP, Brazil.
Alberto J da S DuarteLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM 56), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, BR. Av. Dr. Enéas Carvalho de Aguiar, 470. IMT II, 3° Andar, São Paulo 05403-000, SP, Brazil.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BR

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 88887.472042/2019-00Coordenação de Aperfeicoamento de Pessoal de Nível Superior 88887.511267/2020-00National Council for Scientific and Technological Development 302945/2019-9São Paulo Research Foundation 2016/25212-9São Paulo Research Foundation 2018/12460-0São Paulo Research Foundation 2021/06139-7
6 · The paper itself

Abstract

Due to its leading role in fighting infections, the human immune system has been the focus of many studies in the context of Coronavirus disease 2019 (COVID-19). In a worldwide effort, the scientific community has transitioned from reporting about the effects of the novel coronavirus on the human body in the early days of the pandemic to exploring the body's many immunopathological and immunoprotecting properties that have improved disease treatment and enabled the development of vaccines. The aim of this review is to explain what happens to the immune system after recovery from COVID-19 and/or vaccination against SARS-CoV-2, the virus that causes the disease. We detail the way in which the immune system responds to a SARS-CoV-2 infection, including innate and adaptive measures. Then, we describe the role of vaccination, the main types of COVID-19 vaccines and how they protect us. Further, we explain the reason why immunity after COVID-19 infection plus a vaccination appears to induce a stronger response compared with virus exposure alone. Additionally, this review reports some correlates of protection from SARS-CoV-2 infection. In conclusion, we reinforce that vaccination is safe and important in achieving herd immunity.

Indexed as

cellular responsecorrelates of protectionCOVID-19herd immunityhumoral responserecovered patientstransmissionvaccines

Identifiers

PMID34833028
PMCPMC8619084
OpenAlexW3208636591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.